Skip to content

Randomized controlled trial of San-Ren Run-Chang prescription on the intervention of constipation-type irritable bowel syndrome

Key techniques and outcome research for therapeutic effect of traditional Chinese medicine as complex intervention based on holistic system and pattern differentiation & prescription

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043933
Enrollment
Unknown
Registered
2021-03-05
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome-constipation

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Comply with IBS C Roman IV diagnostic standard; 2) Aged between 18 and 70 years, gender is not limited; 3) Have not taken any medication related to the disease within at least one week before entering the study, and have not participated in any other ongoing study; 4) Colonoscopy was performed within 1 year (colon polyps, inflammatory bowel disease and other organic lesions were excluded); 5) Voluntary subject and informed consent signed by the participant; 6) Frequent residence in the location of treatment is conducive to treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1) Alternate diarrhea and constipation with IBS; 2) Patients with previous heart, liver and kidney tumors and organic lesions or patients with mental illness; 3) Patients with previous gastrointestinal tumors and organic lesions, such as pancreatitis, intestinal polyps (not including polypectomy for more than half a month), intestinal diverticulum, history of colon or rectal cancer, inflammatory bowel history, intestinal tuberculosis, etc.; 4) Previous metabolic diseases affecting digestive tract motility, such as thyroid disease and diabetes mellitus; 5) People with previous gastrocardiac syndrome and lactase deficiency; 6) Allergic constitution or allergic to the components of the drug under study; 7) Pregnant or lactating women, and female patients with recent family planning; 8) Previous abdominal or pelvic surgery, such as cholecystectomy; 9) People who are taking other Chinese medicine for treatment; 10) According to the researchers' judgment, patients with conditions that reduce the possibility of enrolment or complicate enrolment, such as frequent changes in work environment, are prone to loss of follow-up.

Design outcomes

Primary

MeasureTime frame
Irritable bowel syndromes symptom severity score;

Countries

China

Contacts

Public ContactTao Liu

Wangjing Hospital China Academy of Chinese Medicine Sciences

ltlyf2@163.com+86 13521218699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026